Feedback
Settings

Settings

Goto Application

657,231 results
Offices all Languages en Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12Q

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 65,724
1.20250320546System and Kit for Amplification and Detection Targeting Multiplex DIPs
US - 16.10.2025
Int.Class C12Q 1/6844
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6844Nucleic acid amplification reactions
 Appl.No 19000854 Applicant SOUTHERN MEDICAL UNIVERSITY Inventor Bofeng ZHU

A system for multiplex amplification and detection targeting 73 DIP loci and an application thereof. The system includes a set of primers and an amplification premix composition, wherein the set of primers target each of 73 DIP loci. The present system is capable of simultaneously detecting 73 DIP loci in a single reaction on various types of samples, and thus provides a high-performance novel solution for biogeographical ancestry inference of the five major intercontinental populations including African, European, East Asian, South Asian and Native American populations other than American Mestizos and the intra-East Asian populations including Han Chinese, Southeast Asian and Japanese populations.

2.20250320559METHODS RELATING TO IMPAIRED RESPIRATORY HEALTH THERAPEUTICS
US - 16.10.2025
Int.Class C12Q 1/6883
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
 Appl.No 19002911 Applicant Northwestern University Inventor Ravi KALHAN

The present disclosure provides include kits, compositions, and methods related to impaired respiratory health (e.g., diseases and conditions relating to lung injury). In particular, the present disclosure provides include kits, compositions, and methods for quantifying protein biomarkers associated with impaired respiratory health and assessing the risk of, monitoring, treating and/or preventing, interstitial lung diseases (ILDs).

3.20250322927MODELS FOR PREDICTING MUTANT P53 FITNESS AND THEIR IMPLICATIONS IN CANCER THERAPY
US - 16.10.2025
Int.Class G16H 20/17
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
20ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
10relating to drugs or medications, e.g. for ensuring correct administration to patients
17delivered via infusion or injection
 Appl.No 18546762 Applicant Memorial Sloan-Kettering Cancer Center Inventor Benjamin GREENBAUM

The present technology relates to methods, computing devices, and systems for predicting the fitness of mutant p53 based on the loss of transcription factor function and immunogenicity of a particular TP53 mutation. The fitness of mutant p53 may be used to determine whether a patient will benefit from a particular anti-cancer therapy such as immune checkpoint inhibitor therapy, adoptive T-cell therapy, or prophylactic cancer vaccine therapy.

4.WO/2025/217501PANEL FOR DETECTING WOUND PATHOGENS
WO - 16.10.2025
Int.Class C12Q 1/689
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6888for detection or identification of organisms
689for bacteria
 Appl.No PCT/US2025/024251 Applicant LIFE TECHNOLOGIES CORPORATION Inventor WEI, Changfu
Described herein are compositions, methods, and kits for detecting wound pathogens. One embodiment described herein is primer pairs and probes for individual, simultaneous, or sequential multiplex polymerase chain reaction (PCR) based assays for the detection of Acinetobacter baumannii, Bacteroides fragilis, Clostridium perfringens, Enterobacter cloacae, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Klebsiella pneumoniae, Klebsiella Oxytoca, Klebsiella aerogenes, Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa, Serratia marcescens, Staphylococcus aureus, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus pyogenes, Streptococcus anginosus, Staphylococcus lugdunensis, Providencia stuartii, Stenotrophomonas maltophilia, Morganella morganii, Citrobacter koseri, Citrobacter freundii, Citrobacter braakii, Peptoniphilus asaccharolyticus, Peptoniphilus harei, Peptoniphilus ivorii, Peptostreptococcus anaerobius, Finegoldia magna, Clostridium septicum, Paeniclostridium sordellii (Clostridium sordellii), Clostridium novyi A, B, Clostridium histolyticum, Staphylococcus epidermidis, Staphylococcus haemolyticus, Corynebacterium striatum, Candida albicans, Candida auris, Candida glabrata, Candida krusei, Candida parapsilosis, or Candida tropicalis.
5.WO/2025/213721COMPOSITE AMPLIFICATION DETECTION SYSTEM CONTAINING 73 POLYMORPHIC DIP LOCI AND USE THEREOF
WO - 16.10.2025
Int.Class C12Q 1/6888
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6888for detection or identification of organisms
 Appl.No PCT/CN2024/121972 Applicant SOUTHERN MEDICAL UNIVERSITY Inventor ZHU, Bofeng
The present invention relates to the technical field of nucleic acid detection, in particular to a composite amplification detection system containing 73 polymorphic DIP loci and a use thereof. The composite amplification detection system comprises a primer combination and a composite amplification premix. The primer combination targets 73 DIP loci, respectively. The composite amplification detection system can detect 73 DIP loci simultaneously by means of one reaction, is suitable for various tissue types of samples, and provides a new high-resolution detection solution for biogeographical ancestry inference for major five continental populations, including African, European, East Asian, South Asian, and non-admixed South American populations, and East Asian populations, including Southeast Asian ethnic groups, Han Chinese, Japanese, and etc.
6.WO/2025/217516METHODS AND RELATED ASPECTS FOR MONITORING ANTIRETROVIRAL DRUG THERAPY
WO - 16.10.2025
Int.Class G01N 33/543
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
543with an insoluble carrier for immobilising immunochemicals
 Appl.No PCT/US2025/024276 Applicant THE JOHNS HOPKINS UNIVERSITY Inventor ARROYO, Netzahualcoyotl
Provided herein are methods of detecting an antiretroviral therapeutic (ART) agent in a sample from a subject. In some embodiments, the methods include contacting the sample that comprises the ART agent with a plurality of biomolecular receptors such that one or more of the biomolecular receptors undergo conformational changes when the biomolecular receptors bind the ART agent, and detecting one or more detectable signals produced when the biomolecular receptors undergo the conformational changes using a detector. Related devices, kits, systems, computer readable media, and additional methods are also provided.
7.20250321227DUAL-MODE ELECTROCHEMICAL POINT-OF-CARE DETECTION, QUANTIFICATION AND PROFILING OF PATHOGENS
US - 16.10.2025
Int.Class G01N 33/543
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
543with an insoluble carrier for immobilising immunochemicals
 Appl.No 18866658 Applicant THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION Inventor Neta SAL-MAN

The present invention relates to diagnostic platform. More specifically, the invention relates to a dual platform composed of a detection and quantification unit and a characterization unit, systems, kits, methods and uses thereof in detection, quantification and characterization of pathogens, the system comprising monoclonal-antibody-based biosensor chips, for detection and/or quantification of pathogens in a sample, and substrate-based biosensor chips for enzymatically profiling the pathogen in the sample.

8.20250320542SPATIALLY BARCODED SURFACES
US - 16.10.2025
Int.Class C12Q 1/6806
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6806Preparing nucleic acids for analysis, e.g. for polymerase chain reaction assay
 Appl.No 19252879 Applicant Cellanome, Inc. Inventor Stephen C. MACEVICZ

The systems and methods described herein are directed to methods of making spatially barcoded surfaces by a spatially restricted release of unique oligonucleotide barcodes from beads.

9.20250320553METHOD AND DETECTION KIT FOR THE DETECTION OF PYROGENS IN BIOLOGICAL SAMPLES
US - 16.10.2025
Int.Class C12Q 1/6876
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
 Appl.No 18870566 Applicant Minerva Biolabs GmbH Inventor Dirk Vollenbroich

In a method and a detection kit for the detection of pyrogens in a biological sample, immune cells are brought into contact with the sample, which may contain pyrogens, whereby the expression of immunomodulatory mediators takes place, wherein after lysis of the immune cells the nucleic acids of the immune cells are extracted and the expression of immunomodulatory mediators is detected by means of PCR. At least one of three different cytokines/chemokines are detected in parallel. The method and the detection kit can be used for the detection of endotoxin and non-endotoxin pyrogenic contaminations in a medicinal sample.

10.20250320560METHOD OF TREATING OBESITY WITH PRECISION MEDICINE PANEL
US - 16.10.2025
Int.Class C12Q 1/6883
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
 Appl.No 19176898 Applicant Justin Jacob FARAJZADEH Inventor Justin Jacob FARAJZADEH

The present invention provides a method for precision anti-obesity therapy, utilizing a proprietary panel of genetic variants to predict individual patient response to weight-loss medications as well as a related companion diagnostic. In particular, the method analyzes variants in genes including GLP-1 R, CNR1, TCF7L2, DPP4 and others, which have established associations with drug efficacy and metabolism in obesity treatment. By genotyping these markers, the method guides selection and dose optimization of specific anti-obesity medications—such as GLP-1 receptor agonists, metformin, SGLT2 inhibitors, and DPP4 inhibitors—tailored to the patient's genetic profile. Notably, GLP-1R polymorphisms (e.g., rs6923761) are leveraged as especially predictive indicators of enhanced weight loss response to GLP-1 receptor agonists. Through this innovative genetic profiling approach, the invention enables personalized treatment strategies that maximize efficacy, minimize trial-and-error in drug choice, and reduce adverse effects, thereby embodying the principles of precision medicine in obesity care.

# -